



## CLINICAL RESEARCH ARTICLE

# Neonatal intermittent hypoxemia events are associated with diagnosis of bronchopulmonary dysplasia at 36 weeks postmenstrual age

Thomas M. Raffay<sup>1</sup>, Andrew M. Dylag<sup>2</sup>, Abdus Sattar<sup>3</sup>, Elie G. Abu Jawdeh<sup>4</sup>, Shufen Cao<sup>5</sup>, Benjamin M. Pax<sup>6</sup>, Kenneth A. Loparo<sup>6</sup>, Richard J. Martin<sup>1</sup> and Juliann M. Di Fiore<sup>1</sup>

**BACKGROUND:** Bronchopulmonary dysplasia (BPD) is a chronic lung disease and major pulmonary complication after premature birth. We have previously shown that increased intermittent hypoxemia (IH) events have been correlated to adverse outcomes and mortality in extremely premature infants. We hypothesize that early IH patterns are associated with the development of BPD.

**METHODS:** IH frequency, duration, and nadirs were assessed using oxygen saturation (SpO<sub>2</sub>) waveforms in a retrospective cohort of 137 extremely premature newborns (<28 weeks gestation). Daily levels of inspired oxygen and mean airway pressure exposures were also recorded.

**RESULTS:** Diagnosis of BPD at 36 weeks postmenstrual age was associated with increased daily IH, longer IH duration, and a higher IH nadir. Significant differences were detected through day 7 to day 26 of life. Infants who developed BPD had lower mean SpO<sub>2</sub> despite their exposure to increased inspired oxygen and increased mean airway pressure.

**CONCLUSIONS:** BPD was associated with more frequent, longer, and less severe IH events in addition to increased oxygen and pressure exposure within the first 26 days of life. Early IH patterns may contribute to the development of BPD or aid in identification of neonates at high risk.

*Pediatric Research* (2019) 85:318–323; <https://doi.org/10.1038/s41390-018-0253-z>

## INTRODUCTION

Bronchopulmonary dysplasia (BPD) is one of the most common serious pulmonary morbidities of prematurity. Approximately 10–15,000 US infants develop BPD annually, at a cost estimated to exceed \$2.5 billion.<sup>1,2</sup> Infants with BPD have longer initial hospitalizations<sup>3</sup> and frequent childhood readmissions,<sup>4</sup> increased risk for neurodevelopmental impairments,<sup>5</sup> and potentially life-long deficits in pulmonary function.<sup>1,6</sup> BPD has a negative impact on the quality of life among both patients and caregivers.<sup>5,7</sup> Approximately 40% of extremely low gestational age newborns (ELGAN) cared for at tertiary academic centers will be diagnosed with BPD, defined as an oxygen requirement at 36 weeks postmenstrual age (PMA), with increased incidence amongst the most premature infants.<sup>8</sup> Despite advances in neonatal care, the incidence of BPD among ELGAN survivors remains largely unchanged.<sup>8,9</sup>

The pathogenesis of BPD is an ongoing process of injury and recovery occurring in a developmentally immature lung beginning shortly after birth.<sup>10</sup> Following an initial period of respiratory stability, many ELGANs experience pulmonary deterioration during the second week of life associated with a progressive increase in intermittent hypoxemia (IH) events<sup>11</sup> and greater inspired oxygen and positive pressure needs.<sup>12</sup> Oxygen

and positive pressure exposures during the early days and weeks of postnatal life are linked with the development of BPD,<sup>13,14</sup> but the temporal contribution of IH is unclear.

During the first 4 weeks of a premature infant's life, IH increases from approximately 40 to over 100 events per day due to immature breathing patterns,<sup>15</sup> inefficient gas exchange,<sup>16</sup> and/or diminished oxygen stores.<sup>17</sup> Thus IH has received increased attention in the pathogenesis of neonatal morbidity and mortality.<sup>18–21</sup> IH events themselves have the potential to create a proinflammatory cascade<sup>22</sup> and oxidative stress<sup>23,24</sup> which have both been implicated in the causation pathway of BPD.<sup>1,10</sup> Therefore, the aim of this study was to investigate the association of IH patterns with development of BPD at 36 weeks PMA.

## PATIENTS AND METHODS

### Study design and population

A retrospective cohort study of preterm infants (24 0/7 weeks–27 6/7 weeks gestation) from 2005 to 2009 at the tertiary level 4 NICU at Rainbow Babies & Children's Hospital in Cleveland, Ohio were reviewed for hospitalization data. In a sample of convenience that expanded upon a previously published cohort,<sup>18</sup> infants in whom daily respiratory support and continuous oxygen saturation

<sup>1</sup>Division of Neonatology, Rainbow Babies & Children's Hospital, Department of Pediatrics, Case Western Reserve University, Cleveland, OH, USA; <sup>2</sup>Division of Neonatology, Golisano Children's Hospital, Department of Pediatrics, University of Rochester, Rochester, NY, USA; <sup>3</sup>Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA; <sup>4</sup>Division of Neonatology, Kentucky Children's Hospital, Department of Pediatrics, University of Kentucky, Lexington, KY, USA; <sup>5</sup>Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH, USA and <sup>6</sup>Department of Electrical Engineering and Computer Science & Institute for Smart, Secure and Connected Systems, Case Western Reserve University, Cleveland, OH, USA  
Correspondence: Juliann M. Di Fiore (jmd3@case.edu)

Received: 6 September 2018 Revised: 20 November 2018 Accepted: 23 November 2018

Published online: 12 December 2018

**Table 1.** Patient characteristics

	No BPD ( <i>n</i> = 90)	BPD ( <i>n</i> = 47)	<i>p</i> -value
Gestational age (weeks) <sup>a</sup>	26.6 (25.5–27.3)	25.7 (25.0–26.6)	0.002
Birth weight (g) <sup>a</sup>	878 (741–1010)	760 (620–870)	<0.001
Male sex, <i>n</i> (%)	41 (45.5%)	29 (61.2%)	0.073
Race (Black), <i>n</i> (%)	52 (57.8%)	27 (57.4%)	0.97
Caffeine therapy duration (days) <sup>b</sup>	49.3 ± 16.8	54.0 ± 17.7	0.13
Caffeine therapy initiation (days of age) <sup>a</sup>	2 (1–2)	2 (1–4)	0.17
Severe intraventricular hemorrhage, <i>n</i> (%)	6 (6.7%)	5 (10.6%)	0.42
Sepsis, <i>n</i> (%)	22 (24.4%)	11 (23.4%)	0.89

<sup>a</sup>Median (25–75%iles)  
<sup>b</sup>Mean (±SD)

monitoring were documented during the first 4 weeks of life and who survived to 36 weeks postmenstrual age (PMA) were included. Infants with congenital malformations were excluded. As this study included previously acquired data, Rainbow Babies & Children's Hospital Institutional Review Board approved a waiver of consent.

#### Data Collection

Intermittent hypoxemia (IH) events were archived using high-resolution pulse oximetry data continuously recorded from postnatal day of life 1 to 28. Oxygen saturation (SpO<sub>2</sub>) data were acquired continuously with a 2 s averaging and a 0.5 Hz sampling rate (Masimo Radical; Irving, CA). As we have previously described,<sup>18</sup> IH was identified using customized software (Matlab, Natick, MA) and defined as a SpO<sub>2</sub> of ≤ 80% for ≥ 10 s and ≤ 180 s duration. For each infant, the number of IH events was calculated for each day of life. Additionally, SpO<sub>2</sub> nadir of events, IH durations, and IH frequency characteristics were analyzed. During the monitoring periods there were infrequent times when signal loss occurred due to infants not being monitored, corrupt files, and noise or motion artifact. Periods with 0% SpO<sub>2</sub> or 0 bpm for heart rate were considered artifact and removed from the data stream with the remaining data analyzed in 24 h sliding windows. Large areas of missing data, i.e., ≥ 24 h, were treated as missing cells in the statistical analysis.

Hospital charts were reviewed for birth history and daily values of weight, treatment with caffeine, presence and level of respiratory support including mechanical ventilation, CPAP, nasal cannula, and supplemental oxygen were documented. Unit policy was to dose maintenance caffeine citrate at 5–10 mg/kg/day based on clinical effect, serum caffeine levels were not routinely monitored. Supplemental oxygen was recorded as the fraction of inspired oxygen (FiO<sub>2</sub>) at the end of defined 6 h periods (0:00, 6:00, 12:00, and 18:00) and the maximum level for that day, and daily cumulative exposures were calculated as previously described<sup>25</sup> and reported as an area-under-the-curve exposure by day.<sup>13,25</sup> Mean airway pressure (MAP) was recorded as the highest documented exposure of each day. In patients who were supported by a nasal cannula, effective FiO<sub>2</sub> was estimated using the formula described in the STOP-ROP trial<sup>26</sup> and generation of mean airway pressure by nasal cannula flow was calculated by the formula published by Wilkinson et al.<sup>27</sup>

In this study, bronchopulmonary dysplasia was diagnosed by the National Institutes of Health (NIH) physiologic definition as described by Walsh et al.<sup>28</sup> Briefly, infants were assessed at 36 weeks PMA, those on positive pressure or receiving ≥ 30% oxygen were given the diagnosis of BPD, infants on < 30% oxygen nasal cannula or oxygen hood underwent a step-wise reduction in supplemental oxygen down to room air and were continuously monitored for 60 min—infants with SpO<sub>2</sub> < 88% were diagnosed


with BPD, those who remained ≥ 88% were labeled as “no BPD.” Severe intraventricular hemorrhage (IVH) was made by radiologic diagnosis of a Grade 3 or 4 IVH by head ultrasound during hospitalization. Sepsis was designated by culture positive bacteremia or fungemia.

#### Data analysis

Statistical analysis was performed on daily averages of IH frequency, duration, nadir of events, etc. computed for each subject. A two-sided *t*-test or Mann–Whitney *U*-test was used for patient characteristic comparisons between “BPD” and “no BPD” groups after testing for normalcy. In this study, BPD was defined using the NIH physiologic definition at 36 weeks PMA, but previous definitions of BPD have also used 28 days of life.<sup>2</sup> Therefore, comparisons of time-course trajectories were restricted to before 28 days of life. Summary statistics are presented as means ± standard deviation (SD) or median (25–75% quartiles) and *n* (percent) for continuous and categorical variables, respectively. Longitudinal profiles of oxygen saturation waveform measures were modeled and compared between two groups of infants (BPD vs no BPD) using linear mixed models with cubic splines.<sup>18</sup> Modeling the curvilinear trajectory of each outcome with knots at 7, 14, 21, and 26 days adequately represented the infants' profiles with lower AIC (Akaike Information Criterion) values. Models included covariates of gestational age, birth weight, race, sex, multiple gestations, and their interactions with terms involving day.<sup>18</sup> The linear mixed effects models included random intercepts and slopes, and were modeled using unstructured variance covariance matrices that resulted in distinct estimates of all variance and covariance parameters. Correlations among the repeated measures obtained from an infant were modeled by a first-order autoregressive structure. For better model fitting, a logarithmic or square root transformation was applied when the original data were skewed. The maximum likelihood estimation approach was used in estimating all parameters of the model. Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and longitudinal graphs were created using R software version 3.5.1 (R Foundation, Vienna, Austria).

#### RESULTS

The study population included 137 infants, of whom 47 (34%) were diagnosed with the NIH physiologic definition of BPD at 36 weeks PMA. Population characteristics of this cohort showed that infants with BPD were of a lower average gestational age and a lower average birth weight (Table 1). There were no significant differences observed between infant groups for sex, race, severe IVH, or sepsis. As expected, infants with BPD had longer median days of exposure to supplemental oxygen (71 (66–75) vs 32 (17–53) days, *p* < 0.0001) and positive pressure (71 (64–75) vs 45



**Fig. 1** Patterns of Hypoxemia during the First Four Weeks of Life. Longitudinal daily means ( $\pm$ SEM) of bronchopulmonary dysplasia (BPD) group (triangles) vs No BPD group (circles). Lines indicate covariate adjusted modeling. Mean oxygen saturations (SpO<sub>2</sub>) (a) was significantly lower in the BPD group at days 7, 14, 21, and 26 ( $p < 0.001$ ). Frequency of intermittent hypoxemia (IH) events (b) was significantly increased in the BPD group at days 21 and 26 ( $p \leq 0.01$ ). Mean duration of IH events (c) was significantly increased in the BPD group at days 14, 21, and 26 ( $p \leq 0.001$ ). SpO<sub>2</sub> nadir of IH events (d) was higher at days 7 and 14 ( $p \leq 0.001$ )

(32–61) days,  $p < 0.0001$ ) at 36 weeks PMA. One-hundred thirty-six of the 137 study infants received caffeine therapy; day of life initiated and duration of treatment did not significantly differ between groups.


After adjusting for day of life, gestational age, birth weight, race, sex, and multiple gestations, the mean SpO<sub>2</sub> of BPD infants was significantly lower at the predefined curvilinear knots at 7 ( $p = 0.003$ ), 14 ( $p = 0.008$ ), 21 ( $p = 0.0004$ ), and 26 days of life ( $p = 0.002$ ) (Fig. 1a). Intermittent hypoxemia frequency increased dramatically between the first and third weeks of life in this cohort of ELGANs with a significantly higher occurrence of IH in the BPD group at curvilinear knots at 21 ( $p = 0.01$ ) and 26 days of life ( $p = 0.007$ ) (Fig. 1b). Infants diagnosed with BPD also had longer IH events, with differences detected at curvilinear knots at days 14 ( $p = 0.001$ ), 21 ( $p = 0.0005$ ), and 26 days of life ( $p = 0.0002$ ) (Fig. 1c). Interestingly, the BPD group had higher IH nadirs on average, with divergence in IH nadirs at curvilinear knots at 7 ( $p = 0.001$ ) and 14 days of life ( $p = 0.0004$ ) (Fig. 1d). IH events occurring 1–20 min apart diverged between groups at curvilinear knots at days 21 ( $p = 0.0003$ ) and 26 ( $p = 0.0007$ ) (Fig. 2b) with a trend toward a higher incidence of IH < 1 min apart at day 26 ( $p = 0.052$ ) (Fig. 2a). There were relatively few events occurring >20 min apart with no significant differences observed between infant groups (Fig. 2c).

Among the BPD group, levels of inspired oxygen (Fig. 3a) and mean airway pressure (MAP) from both invasive and non-invasive positive pressure respiratory support (Fig. 3b) were significantly higher at the predefined curvilinear knots at 7, 14, 21, and 26 days of life (all  $p < 0.0001$ ).

## DISCUSSION

Our findings demonstrate an association between temporal patterns of IH and BPD in extremely preterm infants. Within the first 26 days of life, we observed increased IH event frequency and durations, and elevated IH nadirs among ELGANs diagnosed with BPD at 36 weeks PMA. BPD was also associated with early exposure to increased supplemental oxygen and mean airway pressure. Level and duration of respiratory therapy have been well described in the injury pathways of BPD and significant differences between exposure groups are observed relatively early.<sup>13,14</sup> This study has shown that temporal patterns of IH may play a role as an additional early marker for future diagnosis of BPD.

The first 4 weeks of life are characterized by a rapid and profound increase in postnatal destabilization.<sup>29</sup> Previous data have shown a 3-fold increased incidence of BPD in newborns with low or decreasing supplemental oxygen and ventilator



**Fig. 2** Stratification of events by time interval during the first 4 weeks of life. Longitudinal daily means ( $\pm$ SEM) of bronchopulmonary dysplasia (BPD) group (triangles) vs No BPD group (circles). Lines indicate covariate adjusted modeling. Intermittent hypoxemia (IH) events with a time interval between events of <1 min apart (a), 1–20 min apart (b), and >20 min apart (c). IH events occurring between 1 and 20 min apart were significantly increased in the BPD group at days 21 and 26 ( $p < 0.001$ ). Events <1 min apart or >20 min apart did not significantly differ between groups


requirements in the first week of life that deteriorate with increased  $\text{FiO}_2$  and respiratory support in the second postnatal week.<sup>12</sup> IH events among our study cohort also indicate a pattern of pulmonary deterioration in the second week, with infants that went on to develop BPD displaying marked increases in daily IH events into the third week of life. The trajectory of IH during this time period may provide additional insight on the likelihood of the diagnosis of BPD at 36 weeks PMA.

Previous studies have shown an association between IH and morbidity in neonates. For example, IH frequency and time spent in hypoxemia are increased in premature infants that develop severe retinopathy of prematurity,<sup>11</sup> neurodevelopmental disabilities including risk for cerebral palsy,<sup>19,20</sup> and death.<sup>20,21</sup> While IH commonly occurs in infants already diagnosed with BPD,<sup>30</sup> a paucity of clinical data exists regarding the association of these early neonatal IH events and BPD risk. Newborn hyperoxic animal models have shown that superimposed IH may potentiate a more severe BPD phenotype.<sup>31–34</sup>

The specific patterns of daily IH events have also been investigated in neonatal morbidity and mortality.<sup>18,20,21</sup> Specifically, IH events occurring between 1 and 20 min apart or those of a duration >1 min have been linked to retinopathy of prematurity requiring laser surgery and late death or disability.<sup>18,20</sup> This pattern of increased IH events occurring 1–20 min apart and of a longer average duration was also relevant in our BPD outcome, as detected at postnatal day 21 and day 14, respectively. An animal model of induced IH describes a burst of superoxide during hyperoxic recovery that peaks at 5 min and returns to baseline over 20 min that may indicate a critical window of IH induced oxidative stress.<sup>24</sup> There was a trend towards an increase in IH < 1 min apart at day of life 26 that was not previously seen in infants with severe ROP.<sup>18</sup> Further investigations of detrimental IH patterns in experimental BPD, as well as, observational studies in high-risk infants are needed.

While the BPD cohort had increased use and levels of supplemental oxygen and positive pressure during the first month of life, they continued to have more frequent and longer duration IH events with a lower mean  $\text{SpO}_2$ . We have previously reported in infants with severe ROP the nadir of IH events to be higher.<sup>18</sup> Again, we observe this pattern of more frequent, longer duration, yet higher IH nadirs in infants who were diagnosed with BPD. We speculate that infants with frequent and greater duration IH due to immature breathing patterns may be clinically perceived to require elevated levels of supplemental oxygen which may successfully increase IH nadirs but also potentially contributes to the development of BPD. We were unable to account for transient increases in supplemental  $\text{FiO}_2$  at the bedside in response to an acute or sustained IH event, but speculate that a lower oxygen reserve and a tendency to desaturate<sup>35</sup> may be indicative of infants with more severe lung disease who proceed on to develop BPD. As such, it is important to note that our study is unable to identify a sequence of causation. We cannot conclude what came first—early parenchymal lung disease and worse lung function predisposing infants to increased IH events and diagnosis of BPD or frequent IH events in the setting of immature lung and respiratory control leading to lung injury and diagnosis of BPD. Translational animal models would indicate that neonatal IH alone is unlikely to cause parenchymal and mechanical BPD lung changes,<sup>31,32</sup> but IH in the setting of supplemental oxygen creates an equal or more severe BPD phenotype.<sup>31–34</sup> Taken together, IH likely has a role in both prolonging neonatal exposures to oxygen and positive pressure in a still developing lung while also contributing to additional lung injury.

Duration and initiation of caffeine therapy was comparable between infant groups with all but one infant treated with caffeine. Caffeine is among the most effective therapies for the



**Fig. 3** Inspired oxygen and mean airway pressure during the first 4 weeks of life. Longitudinal daily means ( $\pm$ SEM) of bronchopulmonary dysplasia (BPD) group (triangles) vs No BPD group (circles). Lines indicate covariate adjusted modeling. Mean fraction of inspired oxygen (FiO<sub>2</sub>) (a) was significantly higher in the BPD group at days 7, 14, 21, and 26 ( $p < 0.0001$ ). Mean airway pressure (MAP) (b) was significantly higher in the BPD group at days 7, 14, 21, and 26 ( $p < 0.0001$ )

prevention of BPD.<sup>36</sup> Caffeine has been shown to significantly decrease the frequency of IH events compared to placebo<sup>37</sup> most likely through stabilization of an immature respiratory drive and prevention of apnea.<sup>15</sup> Our data collection did not include chest impedance to correlate apnea with IH events, but it is speculated that caffeine reduces the duration of exposure to noxious supplemental oxygen and positive pressure thereby decreasing an infant's risk for developing BPD, particularly when started relatively early in premature infants requiring respiratory support.<sup>38</sup> Diminished IH events may in-part also explain the role of prophylactic caffeine in BPD prevention.

This study is a retrospective secondary analysis of an ELGAN cohort of convenience<sup>18</sup> to investigate associations of IH and the physiologic diagnosis of BPD at 36 weeks PMA from a single center, which may limit its generalizability to other centers. Variation in practice and definitions of BPD among institutions may also limit our findings, however the NIH consensus definition for BPD attempts to control for variance of indications for supplemental oxygen and correlates with important early childhood morbidity.<sup>4</sup> As supplemental oxygen at 28 days of life is a requirement for the NIH diagnosis of BPD,<sup>1</sup> a final knot at 26 days

of life was chosen for the curvilinear trajectory models. Also, we only examined IH  $\leq 80\%$  during the first 4 postnatal weeks of life; using another threshold or longer duration may have yielded different results. As there is no standard definition for neonatal IH, future studies could focus on multiple thresholds for distinguishing "mild", "moderate", or "severe" hypoxemia. This study used a 2 s averaging time to minimize SpO<sub>2</sub> signal distortion. Anecdotally, many NICUs use a longer averaging time of 8 s which has been shown to have minimal effect on the detection of IH events  $>10$  s as defined in this study.<sup>39</sup> Current oximeters report time spent within defined saturation thresholds. However, future oximeter software upgrades, as well as, central archiving of cardiorespiratory monitoring waveforms could include more detailed analysis of IH patterns as described in this study.

In conclusion, this study demonstrates that premature infants diagnosed with BPD at 36 weeks PMA had increased frequency, duration, and less severe neonatal intermittent hypoxemia episodes during the first 26 days of postnatal life. Neonates who go on to develop BPD have lower baseline SpO<sub>2</sub> despite increased levels of supplemental oxygen and mean airway pressure support. The future implementation of oximeter or central server reporting of detailed oximetry patterns may assist in early identification of infants at risk for BPD.

#### ACKNOWLEDGMENTS

The authors wish to thank Ms. Marisa Mancuso for assisting with chart recovery and data entry and Dr. Curtis Tatsuoka for statistical guidance in approaches to data modeling. T.M.R. is supported by the NIH K08 HL133459-A1. A.M.D. was supported by the NIH T32 HD060537 (PI R.J.M.). R.J.M. and J.M.D. are supported by the NIH U01 HL133643-01 (Co-PI A.M.H. and R.J.M.). A.M.D. is an awardee of the NIH Loan Repayment Program.

#### AUTHOR CONTRIBUTIONS

T.M.R., A.M.D. and J.M.D. contributed to the concept and design, acquisition, and interpretation of data, and drafting of the article. E.G.A. and R.J.M. contributed to the interpretation of data and revised the article for important intellectual content. A.S., S. C., B.M.P. and K.A.L. analyzed and modeled the data and critically revised the article. All authors approved the final version of the article.

#### ADDITIONAL INFORMATION

**Competing interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### REFERENCES

- Davidson, L. M. & Berkelhamer, S. K. Bronchopulmonary dysplasia: chronic lung disease of infancy and long-term pulmonary outcomes. *J. Clin. Med.* **6**, 1–20 (2017).
- Maitre, N. L. et al. Prematurity, Respiratory Outcomes Program. Respiratory consequences of prematurity: evolution of a diagnosis and development of a comprehensive approach. *J. Perinatol.* **35**, 313–321 (2015).
- Cotten, C. M. et al. Prolonged hospital stay for extremely premature infants: risk factors, center differences, and the impact of mortality on selecting a best-performing center. *J. Perinatol.* **25**, 650–655 (2005).
- Ehrenkranz, R. A. et al. Validation of the national institutes of health consensus definition of bronchopulmonary dysplasia. *Pediatrics* **116**, 1353–1360 (2005).
- Sriram, S. et al. Cognitive development and quality of life associated with bpd in 10-year-olds born preterm. *Pediatrics* **141**, e20172719 (2018).
- Vollsaeter, M., Roksund, O. D., Eide, G. E., Markestad, T. & Halvorsen, T. Lung function after preterm birth: Development from mid-childhood to adulthood. *Thorax* **68**, 767–776 (2013).
- McGrath-Morrow, S. A. et al. The impact of bronchopulmonary dysplasia on caregiver health related quality of life during the first 2 years of life. *Pediatr. Pulmonol.* **48**, 579–586 (2013).
- Stoll, B. J. et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. *JAMA* **314**, 1039–1051 (2015).

9. Lapcharoensap, W. et al. Hospital variation and risk factors for bronchopulmonary dysplasia in a population-based cohort. *JAMA Pediatr.* **169**, e143676 (2015).
10. Jobe, A. H. Mechanisms of lung injury and bronchopulmonary dysplasia. *Am. J. Perinatol.* **33**, 1076–1078 (2016).
11. Di Fiore, J. M. et al. A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity. *J. Pediatr.* **157**, 69–73 (2010).
12. Laughon, M. et al. Patterns of respiratory disease during the first 2 postnatal weeks in extremely premature infants. *Pediatrics* **123**, 1124–1131 (2009).
13. Wai, K. C. et al. Early cumulative supplemental oxygen predicts bronchopulmonary dysplasia in high risk extremely low gestational age newborns. *J. Pediatr.* **177**, 97–102 e102 (2016).
14. Laughon, M. M. et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. *Am. J. Respir. Crit. Care Med.* **183**, 1715–1722 (2011).
15. Martin, R. J., Di Fiore, J. M., Macfarlane, P. M. & Wilson, C. G. Physiologic basis for intermittent hypoxic episodes in preterm infants. *Adv. Exp. Med Biol.* **758**, 351–358 (2012).
16. Dimaguila, M. A., Di Fiore, J. M., Martin, R. J. & Miller, M. J. Characteristics of hypoxemic episodes in very low birth weight infants on ventilatory support. *J. Pediatr.* **130**, 577–583 (1997).
17. Abu Jawdeh, E. G., Martin, R. J., Dick, T. E., Walsh, M. C. & Di Fiore, J. M. The effect of red blood cell transfusion on intermittent hypoxemia in elbw infants. *J. Perinatol.* **34**, 921–925 (2014).
18. Di Fiore, J. M. et al. The relationship between patterns of intermittent hypoxia and retinopathy of prematurity in preterm infants. *Pediatr. Res.* **72**, 606–612 (2012).
19. Pillekamp, F. et al. Factors influencing apnea and bradycardia of prematurity - implications for neurodevelopment. *Neonatology* **91**, 155–161 (2007).
20. Poets, C. F. et al. Association between intermittent hypoxemia or bradycardia and late death or disability in extremely preterm infants. *JAMA* **314**, 595–603 (2015).
21. Di Fiore, J. M. et al. Patterns of oxygenation, mortality, and growth status in the surfactant positive pressure and oxygen trial cohort. *J. Pediatr.* **186**, 49–56 e41 (2017).
22. Darnall, R. A. et al. Early postnatal exposure to intermittent hypoxia in rodents is proinflammatory, impairs white matter integrity, and alters brain metabolism. *Pediatr. Res.* **82**, 164–172 (2017).
23. Nanduri, J. et al. Intermittent hypoxia degrades hif-2alpha via calpains resulting in oxidative stress: Implications for recurrent apnea-induced morbidities. *Proc. Natl Acad. Sci. USA* **106**, 1199–1204 (2009).
24. Fabian, R. H., Perez-Polo, J. R. & Kent, T. A. Extracellular superoxide concentration increases following cerebral hypoxia but does not affect cerebral blood flow. *Int J. Dev. Neurosci.* **22**, 225–230 (2004).
25. Stevens, T. P., Dylag, A., Panthagani, I., Pryhuber, G. & Halterman, J. Effect of cumulative oxygen exposure on respiratory symptoms during infancy among vlbw infants without bronchopulmonary dysplasia. *Pediatr. Pulmonol.* **45**, 371–379 (2010).
26. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (stop-rop), a randomized, controlled trial. I: primary outcomes. *Pediatrics*. **105**, 295–310 (2000).
27. Wilkinson, D. J., Andersen, C. C., Smith, K. & Holberton, J. Pharyngeal pressure with high-flow nasal cannulae in premature infants. *J. Perinatol.* **28**, 42–47 (2008).
28. Walsh, M. C., Wilson-Costello, D., Zadell, A., Newman, N. & Fanaroff, A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. *J. Perinatol.* **23**, 451–456 (2003).
29. Edwards, B. A., Sands, S. A. & Berger, P. J. Postnatal maturation of breathing stability and loop gain: The role of carotid chemoreceptor development. *Respir. Physiol. Neurobiol.* **185**, 144–155 (2013).
30. Martin, R. J., Di Fiore, J. M. & Walsh, M. C. Hypoxic episodes in bronchopulmonary dysplasia. *Clin. Perinatol.* **42**, 825–838 (2015).
31. Dylag, A. M. et al. Long-term effects of recurrent intermittent hypoxia and hyperoxia on respiratory system mechanics in neonatal mice. *Pediatr. Res.* **81**, 565–571 (2017).
32. Ratner, V. et al. Hypoxic stress exacerbates hyperoxia-induced lung injury in a neonatal mouse model of bronchopulmonary dysplasia. *Neonatology* **95**, 299–305 (2009).
33. Mankouski, A. et al. Intermittent hypoxia during recovery from neonatal hyperoxic lung injury causes long-term impairment of alveolar development: A new rat model of bpd. *Am. J. Physiol. Lung Cell Mol. Physiol.* **312**, L208–L216 (2017).
34. Chang, M., Bany-Mohammed, F., Kenney, M. C. & Beharry, K. D. Effects of a superoxide dismutase mimetic on biomarkers of lung angiogenesis and alveolarization during hyperoxia with intermittent hypoxia. *Am. J. Transl. Res.* **5**, 594–607 (2013).
35. Di Fiore, J. M. et al. Low oxygen saturation target range is associated with increased incidence of intermittent hypoxemia. *J. Pediatr.* **161**, 1047–1052 (2012).
36. Schmidt, B. et al. Caffeine therapy for apnea of prematurity. *N. Engl. J. Med.* **354**, 2112–2121 (2006).
37. Rhein, L. M. et al. Effects of caffeine on intermittent hypoxia in infants born prematurely: a randomized clinical trial. *JAMA Pediatr.* **168**, 250–257 (2014).
38. Davis, P. G. et al. Caffeine for apnea of prematurity trial: benefits may vary in subgroups. *J. Pediatr.* **156**, 382–387 (2010).
39. Vagedes, J., Poets, C. F. & Dietz, K. Averaging time, desaturation level, duration and extent. *Arch. Dis. Child Fetal Neonatal Ed.* **98**, F265–F266 (2013).